Bio Blast Pharma Appoints Colin Foster As CEO - Quick Facts

(RTTNews) - Bio Blast Pharma Ltd. (ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced the appointment of Colin Foster as its President, Chief Executive Officer or CEO and a member of its Board of Directors, effective immediately.

Dalia Megiddo, MD, co-founder and former Chief Executive Officer, has been named to the newly-created position of Chief Development Officer and will remain a member of the Board of Directors, Bio Blast said.

The company noted that Foster has extensive experience in leading therapeutic, diagnostic, and medical device companies in  and internationally, working across the R&D-to-commercial continuum. He was founder and CEO of iSci Management LLC, a life sciences advisory firm, co-founder and CEO of Optherion, Inc., a venture backed biologics and diagnostics company and prior to that, he was the President and CEO of Bayer Pharmaceuticals Corporation  and Region Head of the North American Pharmaceuticals business of Bayer AG.